(Q36018553)

11 August 2017

1 reference

title

Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule (English)

1 reference

11 August 2017

1 reference

Fliser D

1

1 reference

11 August 2017

1 February 2005

1 reference

European Journal of Clinical Investigation

11 August 2017

1 reference

11 August 2017

35

1 reference

11 August 2017

2

1 reference

11 August 2017

71-79

1 reference

Endothelial function: a critical determinant in atherosclerosis?

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

The L-arginine-nitric oxide pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetrical dimethylarginine: the Uber marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Inhibition of nitric oxide activity by arginine analogs in human renal arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Impact of infectious burden on extent and long-term prognosis of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01457.X

10.1111/J.1365-2362.2005.01457.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15667575